Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $18

Benzinga Newsdesk www.benzinga.com Positive 90.8%

Neg 0% Neu 0% Pos 90.8%

Oppenheimer analyst Leland Gershell maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $10 to $18.